Blackstone Life Sciences is investing $250 million in Anagram Therapeutics to advance ANG003, an oral enzyme replacement therapy…
Articles by Patricia Inácio, PhD
Children with cystic fibrosis who carry two Trikafta-responsive mutations are significantly more likely to reach normal or near-normal…
In people with cystic fibrosis (CF), the timing of organ transplant — lung, liver, or…
Bioversys has entered into an exclusive collaboration and license agreement with Hackensack Meridian Health (HMH) and its…
The lungs of infants and children with cystic fibrosis (CF) show an early, overactive immune response driven by neutrophils…
Researchers at UCLA have developed a nonviral gene-editing strategy that could help pave the way for one-time treatments for people…
A new survey conducted in Germany showed that, in addition to easing symptoms and improving quality of life, Trikafta…
Persistent Pseudomonas aeruginosa infection in people with cystic fibrosis (CF) who have received treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) seems…
Almost 30% of cystic fibrosis (CF) patients who had a lung transplant in the U.S. were prescribed Trikafta…
The Cystic Fibrosis Foundation will invest up to $2.3 million for a company to develop a breath test designed to…